Classer les publications sur l'année
-
Pharmaco-Epidémiologie
Prise en charge de la douleur en mĂ©decine gĂ©nĂ©rale : l’Ă©tude EPIDOL
EMERY C, GEORGE B, GOMAS JM, DELFIEU D, MIMAUD V, GUILLON P, FAGNANI F
Douleurs ; 6(6):366-373
-
Pharmaco-Epidémiologie
Epidemiology of restless legs syndrome in French adults A nationwide survey: The INSTANT Study
TISON F, CROCHARD A, LEGER D, BOUEE S, LAINEY E, EL HASNAOUI A
Neurology ; 65:239-246
-
Pharmaco-Epidémiologie
Effects of dyskinesias in Parkinson’s disease on quality of life and health-related costs : a prospective European study
PECHEVIS C, CLARKE E, VIEREGGE P, KHOSHNOOD B, DESCHASEAUX-VOINET C, BERDEAUX G, ZIEGLER M
Eur J Neurol ; 12:956-963
-
Pharmaco-Epidémiologie
Screening for Alzheimer’s disease with the short cognitive evaluation battery
ROBERT PH, SCHUCK S, DUBOIS B, OLIE JP, LEPINE JP, GALLARDA T, GONI S, TROY S
Dement Geriatr Cogn Disord ; 15:92-98
-
Ăconomie de la santĂ©
Donepezil for the treatment of mild to moderate Alzheimer’s disease in France: the economic implications
FAGNANI F, LAFUMA A, PECHEVIS M, RIGAUD AS, TRAYKOV L, SEUX ML, FORETTE F
Dement Geriatr Cogn Disord ; 17(1-2):5-13
-
Ăconomie de la santĂ©
Patients with Alzheimer’s disease living at home in France: costs and consequences of the disease
RIGAUD AS, FAGNANI F, BAYLE C, LATOUR F, TRAYKOV L, FORETTE F
J Geriatr Psychiatry Neurol ; 16(3):140-145
-
Ăconomie de la santĂ©
Patients with Alzheimer’s disease living at home in France : costs and consequences of the disease
RIGAUD AS, FAGNANI F, BAYLE C, LATOUR F, TRAYKOV L, FLORETTE F
J Geriatr Psychiatry Neurol ; 16(3):140-145
-
Ăconomie de la santĂ©
The Value of Economic Modeling Studies in the Evaluation of Treatment Strategies for Multiple Sclerosis
DETOURNAY B
Value Health ; 5(1):1-2
-
Pharmaco-Epidémiologie
Newly diagnosed unprovoked epileptic seizures: presentation at diagnosis in CAROLE study
JALLON P, LOISEAU P, LOISEAU J, CAROLE, on behalf of Groupe
Epilepsia ; 2001;42 (4): 464-475
-
Pharmaco-Epidémiologie
L’observatoire du traitement mĂ©dical de la maladie d’Alzheimer en neurologie libĂ©rale et les contrĂŽles de qualitĂ© dans les Ă©tudes pharmaco-Ă©pidĂ©miologiques
SIMON T, HINAULT P, GONI S, HOTTON JM, PAUL-DAUPHIN A, GUARD O, DARAN H, JAILLON P
La Lettre du Pharmacologue ; 15(4):74-78
-
Ăconomie de la santĂ©
Les patients atteints d’Alzheimer Ă domicile : coĂ»t et retentissement de la maladie
RIGAUD AS, BAYLE C, FORETTE F, BUTEAU L, FAGNANI F
GĂ©rontologie ; 2001(115): 17-23
-
Pharmaco-Epidémiologie
Direct and indirect costs of Parkinson’s Disease (PD) and L-Dopa-Induced Dyskinesia: a Prospective European Study (Abstract)
PECHEVIS M, CLARKE CE, VIEREGGE P, ZIEGLER M, BERDEAUX G, BARLAND JC, J, GARDNER
Parkinsonian & Related Disorders ; 7(P-WE-383):S106
-
Ăconomie de la santĂ©
Evaluation économique du dispositif transdermique de Fentanyl dans la prise en charge de la douleur cancéreuse
PECHEVIS M, EMERY C, FAGNANI F
La Lettre du Pharmacologue ; 14 (1) ; 10-14
-
Pharmaco-Epidémiologie
DĂ©lais Ă©volutifs des syndromes Ă©pileptiques avant leur diagnostic : rĂ©sultats descriptifs de l’enquĂȘte CAROLE
Groupe CAROLE
Revue de Neurologie ; 2000;156; (5) : 481-490
-
Pharmaco-Epidémiologie
ESPERA study : Applicability of the new ILAE criteria for antiepileptic drug resistance of focal epilepsies in current clinical practice
DE TOFFOL B, DE ZELICOURT M, VESPIGNANI H, FAGNANI F, LAURENDEAU C, LEVY-BACHELOT L, MURAT C, GASALLA T, ARZIMANOGLOU A, VILLANUEVA V
Epilepsy Behav ; 2012;25(2):166-169
  Â